We suggest parameters for future prospective trials with a target blood glucose range of 90–140 mg/dL to guide insulin therapy and that insulin initiation should be guided by the MHG, rather than admission glucose or a patient history of diabetes. The gene discussed is INS; the disease is diabetes mellitus.